跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

SHC216V

Sigma-Aldrich

MISSION®

Targets no known genes from any species

登录查看公司和协议定价
所有图片(1)
别名:
MISSION®, MISSION® Control Transduction Particles, negative control, negative shRNA control, non-target control, non-target shRNA, non-target shRNA control, shRNA control
UNSPSC代码:
12352200
NACRES:
NA.51

质量水平

100
200

产品线

MISSION®

浓度

≥1x106 VP/ml (via p24 assay)

运输

dry ice

储存温度

−70°C

相关类别

一般描述

The MISSION® TRC2 pLKO.5-puro Non-Target shRNA Control Tranduction Particles contain an shRNA insert that does not target any known genes from any species, making it useful as a negative control in experiments using the MISSION® shRNA library clones. This allows one to examine the effect of transduction of a short-hairpin on gene expression and interpret the knockdown effect seen with shRNA clones. Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids. The Non-Target shRNA Control Transduction Particles are provided as 200 uL at 1 x 106 TU/mL via p24 assay.
当使用MISSION® TRC shRNA克隆进行实验时，选择适当对照品是您的实验设计的关键要素，以便准确解释敲低结果。 MISSION对照转导颗粒是监测转导效率的关键阳性对照。
想要查看更多应用数据、实验方案和载体图谱，请访问 sigma.com/shrna。

应用

To see more application data, protocols, vector maps visit sigma.com/shrna.

法律信息

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma.
Manier S
Leukemia, 31(4), 853-860 (2017)
STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation.
Pedroza M
Faseb Journal, 30(1), 129-140 (2016)
Curtis A Clark et al.
Cancer research, 76(23), 6964-6974 (2016-09-28)
PD-L1 antibodies produce efficacious clinical responses in diverse human cancers, but the basis for their effects remains unclear, leaving a gap in the understanding of how to rationally leverage therapeutic activity. PD-L1 is widely expressed in tumor cells, but its
Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer.
Lewis KM
Lung Cancer, 90(2), 182-190 (2015)
Katherine M Lewis et al.
Lung cancer (Amsterdam, Netherlands), 90(2), 182-190 (2015-09-28)
Lung cancer is the leading cause of cancer death in both men and women. Non-small cell lung cancer (NSCLC) has an overall 5-year survival rate of 15%. While aberrant STAT3 activation has previously been observed in NSCLC, the scope of
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门